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To date, eleven countries have been validated as having eliminated trachoma as a public
health problem, including Ghana in 2018. Surveillance for recrudescence is needed both
pre- and post-validation but evidence-based guidance on appropriate strategies is lacking.
We explored two potential surveillance strategies in Ghana.
Methodology/principal findings
Amongst randomly-selected communities enrolled in pre-validation on-going surveillance
between 2011 and 2015, eight were identified as having had trachomatous-inflammation fol-
licular (TF) prevalence�5% in children aged 1–9 years between 2012 and 2014. These
eight were re-visited in 2015 and 2016 and neighbouring communities were also added (“TF
trigger” investigations). Resident children aged 1–9 years were then examined for trachoma
and had a conjunctival swab to test for Chlamydia trachomatis (Ct) and a dried blood spot
(DBS) taken to test for anti-Pgp3 antibodies. These investigations identified at least one
community with evidence of probable recent Ct ocular transmission. However, the approach
likely lacks sufficient spatio-temporal power to be reliable.
A post-validation surveillance strategy was also evaluated, this reviewed the ocular Ct
infection and anti-Pgp3 seroprevalence data from the TF trigger investigations and from the
pre-validation surveillance surveys in 2015 and 2016. Three communities identified as hav-
ing ocular Ct infection >0% and anti-Pgp3 seroprevalence�15.0% were identified, and
along with three linked communities, were followed-up as part of the surveillance strategy.
An additional three communities with a seroprevalence�25.0% but no Ct infection were
also followed up (“antibody and infection trigger” investigations). DBS were taken from all
residents aged�1 year and ocular swabs from all children aged 1–9 years. There was evi-
dence of transmission in the group of communities visited in one district (Zabzugu-Tatale).
PLOS NEGLECTED TROPICAL DISEASES







Citation: Senyonjo L, Addy J, Martin DL,
Agyemang D, Yeboah-Manu D, Gwyn S, et al.
(2021) Surveillance for peri-elimination trachoma
recrudescence: Exploratory studies in Ghana. PLoS
Negl Trop Dis 15(9): e0009744. https://doi.org/
10.1371/journal.pntd.0009744
Editor: Richard Reithinger, RTI International,
UNITED STATES
Received: May 19, 2021
Accepted: August 18, 2021
Published: September 20, 2021
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: All relevant data are
within the manuscript.
Funding: Sightsavers received financial support for
this work from the Coalition for Operational
Research on Neglected Tropical Diseases (grants
NTD-SC 150D & NTD-SC 055), which is funded at
The Task Force for Global Health by the Bill &
Melinda Gates Foundation, the United States
Agency for International Development through its
Neglected Tropical Diseases Program; and UK aid
from the British people. The funders had no role in
There was no or little evidence of continued transmission in other districts, suggesting previ-
ous infection identified was transient or potentially not true ocular Ct infection.
Conclusions/significance
There is evidence of heterogeneity in Ct transmission dynamics in northern Ghana, even 10
years after wide-scale MDA has stopped. There is added value in monitoring Ct infection
and anti-Ct antibodies, using these indicators to interrogate past or present surveillance
strategies. This can result in a deeper understanding of transmission dynamics and inform
new post-validation surveillance strategies. Opportunities should be explored for integrating
PCR and serological-based markers into surveys conducted in trachoma elimination
settings.
Author summary
The goal for trachoma programmes is elimination of trachoma as a public health problem.
This means that ongoing low-level eye-to-eye transmission of the causative bacterium,
Chlamydia trachomatis (Ct), is acceptable. Countries need to implement a suitable surveil-
lance system to identify any return to higher transmission levels. The best methodology
for doing this is not known. We first explored the approach used by Ghana in its standard
programme, which involved monitoring a limited number of randomly selected commu-
nities for evidence of active (inflammatory) trachoma visible in children’s eyes on exami-
nation by trained observers. Although this strategy led to identification of at least one
community that had probably had recent Ct transmission, the approach is unlikely to con-
sistently identify places where return to higher levels of transmission is a risk. We also
explored using information on infection (detected in eye swabs) and antibodies to Ct
(detected in the blood) to identify communities at risk. We found evidence of both persis-
tent eye-to-eye Ct transmission and areas where infection was transient and has now gone
away. We conclude that the use of infection and antibody data for surveillance of tra-
choma appears promising.
Introduction
Trachoma, caused by repeated conjunctival infection with the bacterium Chlamydia trachoma-
tis (Ct), which can progress to trachomatous trichiasis (TT), the in-turning of the eyelids
resulting in at least one eyelash touching the globe of the eye, is the leading infectious cause of
blindness worldwide [1]. It is targeted for global elimination as a public health problem [2]
using the “SAFE” strategy: Surgery to minimize progressive visual loss in individuals who have
TT; mass drug administration [MDA] of Antibiotics; and Facial cleanliness and Environmen-
tal improvement. Elimination as a public health problem can be validated if (1) there is evi-
dence that specific disease prevalence thresholds have been achieved and maintained for a
minimum of two years in the absence of antibiotic MDA in each formerly-endemic evaluation
unit (EU) of a country and (2) a suitable system is in place to identify and manage incident TT
cases [3]. The elimination prevalence thresholds are a trachomatous inflammation—follicular
(TF) prevalence <5% in children aged 1–9 years and a TT prevalence <0.2% amongst
�15-year-olds [3].
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Validation of elimination of trachoma as a public health problem does not require absence
of ocular Ct infection [3–5]. Therefore, after antibiotic MDA has ceased, countries must moni-
tor for potential recrudescence. However, there is no clear definition of trachoma recrudes-
cence or re-emergence, including at what geographical level (community, sub-district or
district) monitoring for it could or should be undertaken. While it may initially seem reason-
able to define recrudescence as the transition of a district that had achieved a TF prevalence of
<5% to subsequently having a TF prevalence�5%, TF prevalence is a lagging indicator as Ct
prevalence declines [6–9] and could also conceivably lag behind Ct prevalence if infection sub-
sequently recrudesced. Waiting until TF prevalence is�5% might therefore lead to missing
opportunities for early intervention. Equally, the observation in some populations of moder-
ate-to-high TF prevalence with low or absent ocular Ct infection raises a concern that other
causes of follicular conjunctival inflammation might trigger an erroneous recrudescence alarm
[10–14]. Either form of systematic misclassification (false negative or false positive) would be
problematic for programmes.
The World Health Organization (WHO) guidance on methods for trachoma pre-validation
surveillance has changed over time. In 2008, WHO recommended that surveillance for active
trachoma be undertaken through examination of school-aged children for TF in 2–4 purpo-
sively selected sites per evaluation unit (EU). Sites in the “least developed and suspected most
endemic” areas of the EU were to be selected [15]. In 2014, a WHO technical consultation [16]
reviewed those recommendations and concluded that the methodology could be unduly influ-
enced by bias and chance, compounded by an inadequate understanding of community-level
factors that might be associated with Ct resurgence. The 2008 guidance was therefore replaced
with a recommendation for pre-validation surveillance in each EU as a population-based sur-
veillance survey carried out at least two years after the last impact survey [16]. There are no for-
mal WHO guidelines regarding post-validation surveillance for active trachoma; this is a
recommended activity of operational research, conducted within collaborations between
health ministries and academic partners [3].
Designing operational research for post-validation surveillance is difficult because the evi-
dence base for evaluation systems—when, where, who and what—is very limited. Several stud-
ies have examined use of serology and nucleic acid amplification tests (NAATs) as alternatives
or adjuncts to TF for this purpose [4,17–22]. It may be possible to employ serology- and
NAAT-based markers to identify communities at increased risk of recrudescence; this could
begin pre- or post-validation [4], potentially in combination with surveillance activities for
other diseases [23].
We present an evaluation of pre- and post-validation surveillance using serology and PCR,
in the hope they can inform future refinement of trachoma programme surveillance strategies.
Methods
Ethical considerations
This research was approved by the Ghana Health Service (GHS) Ethical Review Committee
(03/07/15 & 01/11/18) and the London School of Hygiene & Tropical Medicine Ethics Review
Committee (reference: 10285 & 16169). Written informed consent was received from all par-
ticipants and caregivers of minors, informed assent was also attained from children able to
provide it. Individuals with TF were offered 1% tetracycline eye ointment. Individuals with TT
were referred within the health system for management. This activity was reviewed by CDC
and was conducted consistent with applicable federal law and CDC policy.
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Study area
This evaluation was conducted in two previously trachoma-endemic regions of Ghana: North-
ern and Upper West. In 2008, all districts had achieved the TF elimination prevalence thresh-
old and antibiotic MDA was stopped [24]. In 2018, WHO validated Ghana as having
eliminated trachoma as a public health problem [25,26].
Study design
Two approaches for trachoma surveillance using clinical, antibody and infection indicators
were evaluated to determine how effective they are in identifying on-going transmission and
potential recrudescence.
1. Evaluation of the on-going pre-validation surveillance system, implemented by GHS from
2011–2015. This strategy was based on assessment of the prevalence of TF in children aged
1–9 years in a limited number of randomly selected sites each year. We will refer to these
investigations as the “TF trigger” component of our study; it was done prior to validation,
in 2015–2016.
2. Identification of communities hypothesized to be at potential risk of recrudescence on the
basis of serological and infection data from either the TF trigger investigations or a series of
pre-validation surveillance surveys conducted by GHS in 2015–2016 [25]. These communi-
ties were followed up in 2019. This work explored a potential model for post-validation sur-
veillance. We will refer to the 2019 investigations as the “infection and antibody trigger”
component.
Fig 1 provides an overview of the study methodology and the various components.
TF trigger evaluation
From 2011–2015, GHS implemented an on-going pre-validation surveillance system based on
then-current WHO recommendations [27] consisting of field visits to seven randomly-
selected sites per district per year in 18 EUs: two communities and five primary schools or pre-
schools and the communities in which attending children lived. At those sites, all participants
aged 1–9 years were examined for TF and all available participating adults aged�15 years
were examined for TT. Once a school or community was visited as part of this process, it was
removed from the sampling frame for all subsequent years. Through this methodology, from
2011–2015, a total of eight index communities were identified in which�5% of examined chil-
dren had TF. GHS subsequently examined children for trachoma in up to four communities
neighbouring those index communities; no further communities were found in which�5% of
examined children had TF. Antibiotic MDA was undertaken in the eight index communities
for three years [28]. The final MDA round was completed at least six months prior to the study
investigations outlined below.
In 2015–2016, the eight index communities were each re-visited. For six of the eight com-
munities, up to four neighbouring communities (identified by the health facility staff and
based on proximity) were also visited. For the two districts (Sawla-Tuna-Kalba and Zabzugu-
Tatale, in the northern region) in which more than one index community was identified,
neighbouring communities were only chosen for the index community with the higher TF
prevalence. In Sawla-Tuna-Kalba, the two index communities (Baale and Kema) are adjacent.
All consenting individuals aged�1 year living in the index and neighbouring communities
were examined for signs of trachoma and all children aged 1–9 years had a conjunctival swab
and a dried blood spot (DBS) taken.
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Fig 1. Flowchart depicting study methodology.
https://doi.org/10.1371/journal.pntd.0009744.g001
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Infection and antibody trigger
In 2015–2016, GHS conducted a number of population-based pre-validation surveillance sur-
veys [25]; DBS and ocular swabs were collected from children aged 1–9 years in six of the EUs,
as outlined in Senyonjo et al, 2018 [4]. The infection and antibody trigger method, took a step-
wise approach, reviewing available Ct infection and anti-Pgp3 antibody data from either the
pre-validation surveillance surveys or from the TF trigger investigations. This identified three
communities as having, in 1–9-year-olds, (1) a prevalence of ocular Ct infection >0% and (2) a
prevalence of anti-Pgp3 antibodies�15.0%. These three communities were included in the
infection and antibody trigger investigations, with the expectation that they are the most at
risk for potential recrudescence. For each of these communities, three communities “linked”
to the index community were also invited to participate. The criteria considered for inclusion
of a linked community were:
• Location within 5 km of the index community;
• Presence of a footpath or road directly linking it to the index community;
• Frequent interaction of residents with residents of the index community (based on report by
residents of the index community), including (for example) through attendance of children
at the same pre- or primary school.
Efforts were made to select linked communities from different compass points in relation
to the index community.
Communities located in the same districts as the three index communities (Wa, Sawla-
Tuna-Kalpa, Zabzugu-Tatale) that had a 2016 seroprevalence in 1–9-year-olds of�25.0% but
no Ct infection were also invited to participate.
In February 2019, all consenting individuals aged�1 year in selected communities were
examined for signs of trachoma and had a DBS taken. Children aged 1–9 years also had a con-
junctival swab taken. A maximum of 300 DBS were collected per community, so in larger com-
munities, children aged 1–9 years were exhaustively sampled and individuals aged�10 years
were only sampled in every nth household, with n being the sampling interval calculated to
result in the 300 DBS being collected evenly throughout the sampling frame. Data were also
collected by interview on socio-economic status, access to water and sanitation services, educa-
tion levels, school attendance, number of persons living in the household and compound
(where applicable), and social interactions between children that could facilitate transmission.
Efforts were made to include individuals who were initially absent, with teams returning a
minimum of once to any household where one or more residents were not present at the time
of the team’s first visit.
Data handling
Survey data were collected electronically using secure, Open Data Kit-based Android smart-
phone applications (LINKS, Task Force for Global Health, Atlanta GA, USA, https://
linkssystem.org, for the TF trigger investigations; CommCare, Dimagi Inc., Cambridge MA,
USA, for the infection and antibody trigger investigations). Data were uploaded to a cloud-
located server, which was password-protected with access only available to study investigators.
Clinical assessment
Participating subjects were examined for the five signs of trachoma in the WHO simplified sys-
tem: TF, trachomatous inflammation—intense (TI), trachomatous scarring (TS), TT and
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corneal opacity (CO)[29] by trained graders. Presence of pathology in one or both eyes was
scored as that sign of trachoma.
All graders were ophthalmic nurses certified in 2015 using Global Trachoma Mapping Proj-
ect methodologies [30,31], as previously described [25]. In 2019, graders were given refresher
training on trachoma grading using photos; graders participated only if they achieved a kappa
score of�0.8 for TF in an inter-grader agreement test.
Sample collection
Swabs for Ct PCR were collected by passing a polyester-tipped swab three times across the
upper tarsal conjunctiva of the left eyelid, using a standardised procedure described previously
[4]. Precautions were taken to minimize field contamination of the swabs, including changing
gloves after every sample taken. Negative control air swabs were taken by field teams after
every 50 subjects for the TF trigger investigations and after every 25 subjects for the infection
and antibody trigger investigations; the count restarted when the team moved to a new district.
Samples were kept dry and cool in an ice box in the field.
To collect DBS, the participant’s finger was cleansed using an alcohol-soaked swab before
being pricked using a sterile single-use spring-loaded lancet. Blood was collected directly onto
a filter paper wheel with six projections, each calibrated to absorb 10 μl of blood. The filter
paper wheel was air-dried in the shade before being individually packed in a sealable plastic
bag and stored with desiccant.
Once collected, ocular swabs were stored at 4˚C and transferred within a week on ice packs
to Noguchi Memorial Institute for Medical Research (NMIMR), Accra, Ghana, where they
were stored at -20˚C until the time for analysis. The DBS were also stored at 4˚C and (for the
TF trigger investigations) transferred to NMIMR or (for the infection and antibody trigger
investigations) sent to CDC, Atlanta, where they were stored at -20˚C until being analysed.
Detection of ocular Ct infection and anti-Pgp3 antibody
PCR for both sets of samples was conducted at NMIMR. For the TF trigger investigations,
detection of anti-Pgp3 antibodies was conducted at NMIMR using an enzyme-linked immu-
nosorbent assay (ELISA) as previously described [4]. For the infection and antibody trigger
investigations, antibodies were detected using the multiplex bead array (MBA) platform at
CDC, described elsewhere [32,33].
Conjunctival swabs were eluted using sterile diethylpirocarbonate (DEPC) water and
pooled into groups of five samples using a published pooling strategy [34]. They were then
analysed for the presence of Ct DNA using the GeneXpert CT/NG Assay run on GeneXpert IV
(Cepheid, Sunnyvale CA, USA). For positive pools, component samples were re-tested individ-
ually to identify specific positive(s). Indeterminate pools were re-tested using a new aliquot of
each component sample and a new GeneXpert cartridge. Field control swabs were analysed
individually. Two Ct-positive and two Ct-negative processing controls were run at the begin-
ning of each week.
Statistical analysis
Statistical analyses were conducted using STATA (Version 17, StataCorp, College Station TX,
USA) and R (R Core Team 2014). The threshold to determine a seropositive individual was
calculated using a finite mixture model based on maximum likelihood methods, with a cut-off
for positivity set as four standard deviations from the mean of the seronegative population
[18]. For the MFI-bg values (data from the MBA) data were first log-transformed (log(x+1)),
to accommodate zero values. For the samples analysed by ELISA, the cut-off was calculated as
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1.091 OD450nm; for the samples analysed by MBA, the cut-off for log (MFI-bg+1) was calcu-
lated as 5.724.
Fisher’s exact test was used to assess the homogeneity of seroprevalence estimates between
linked communities.
For the infection and antibody trigger investigations, simple associations between seroposi-
tivity in children aged 1–9 years and potential explanatory factors were evaluated using the
Chi-square test or non-parametric test for trend, as applicable.
Seroconversion rates (SCR, the mean annual rate at which seronegative individuals become
seropositive) were calculated using a simple reverse catalytic model (RCM) fitted to seropreva-
lence in one-year age groups (all ages�1 year), using maximum likelihood estimates [35]. Evi-
dence for a change in SCR over time was conducted through comparisons of paired models,
the first assuming constant transmission intensity, and the second assuming a change in trans-
mission intensity at a specified time point [36].
For the infection and antibody trigger investigations, in communities in and around
Mayido, spatial autocorrelation of household-level TF and seroprevalence (in children aged
1–9 years) within a village boundary was evaluated using Moran’s I index.
Results
TF trigger
A total of 1,869 children aged 1–9 years were present at the time of the survey and enumerated
from across 27 communities (8 index, 19 neighbouring, Table 1). All were examined for signs
of trachoma and had DBS taken. 1,831 DBS were analysed and able to be matched to demo-
graphic data. Of individuals matched to DBS results, 49.0% were female. 1,773 children had an
ocular swab taken.
Only one 1–9-year-old tested (in Kakalapere, Wa District) had a PCR-positive ocular swab.
In this community, the Ct infection prevalence was 1.4%, the seroprevalence by ELISA was
16.2% and the TF prevalence was 5.4%, Table 1. The neighbouring community of Manliyiri
had the highest seroprevalence recorded across the seven communities (28.6%). There was no
evidence of a difference in the seroprevalence (p = 0.13) across sampled communities in Wa,
Fig 2.
Data collected in 2015–2016. Base map: Made with Natural Earth. Free vector and raster
map data @ naturalearthdata.com. https://www.naturalearthdata.com/downloads/10m-
cultural-vectors/
There was an increase in seroprevalence by age, in Baale and neighbouring communities
and likewise for Mampeasem and neighbouring communities, Table 2.
Infection and antibody trigger
The communities included were drawn from the TF trigger investigations described in the
paper and the study published in Senyonjo et al, 2018 [37]. A total of 3,121 individuals were
enumerated and present at the time of field teams’ visits; 52.7% were female. A total of 3,050
DBS were taken from individuals aged�1 year and 2,908 DBS were matched to demographic
data. A total of 1,170 (37.5%) of those enumerated were aged 1–9 years, from whom 1,163 ocu-
lar swabs were taken and analysed.
One community (Mayido) had the highest prevalence of both Ct infection (1.6%) and anti-
Pgp3 antibodies (14.4%) in 1–9-year-olds. Of the three cases of Ct infection identified in
Mayido, two were from the same household. The community with the highest TF prevalence
(Satinjado with 12.9% TF) was linked to Mayido, Table 3. Only one other community had any
Ct infection—this community had only a single case of infection, no TF, and only 5.3% of
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children were positive for anti-Pgp3 antibodies, Table 3. There was no evidence of spatial auto-
correlation of TF at household level in any of the communities in the district of Zabzugu-
Tatale, where Mayido and Satinjado are located. Spatial autocorrelation of household sero-
prevalence was only identified in the community of Kogni (Moran’s I -0.157; p = 0.05), also in
Zabzugu-Tatale.
There was strong evidence (p<0.001) of a change in the SCR at a time point between 6 and
15 years prior to sample collection in each of the three groups of communities evaluated. For
the groups of communities in Sawla-Tuna-Kalba and Wa Districts, the more recent SCR
(SCR2) was significantly lower than the historic rate after the time point of the rate change
(SCR1). In Mayido and surrounding communities of Zabzugu-Tatale District, the more recent
SCR was higher, Table 4.
Table 1. Clinical, serology and conjunctival C. trachomatis (Ct) infection data from children aged 1–9 years in index and neighbouring communities visited as part
of TF trigger-based investigations.


















Baale 6.8% Index 56 0% 0% 16.1% (9) 15.8; 0.004
Kema 6.7% Index�� 94 0% 0% 4.3% (4)
Soma Neighbouring 140 0% 0% 2.1% (3)
Gbonbondouri Neighbouring 119 0% 0% 9.2% (11)
Dani-uuri Neighbouring 47 0% 0% 4.2% (2)
West
Gonja
Mampeasem 6.0% Index 121 1.7% (2) 0% 2.5% (3) 6.1; 0.04
Sakpege Neighbouring 65 3.1% (2) 0% 0%
Lukula Neighbouring 69 0% 0% 7.2% (5)
Zabzugu-
Tatale
Mangoase 7.8% Index 58 1.7% (1) 0% 6.9% (4) 8.3; 0.03
Jatoyili Neighbouring 87 4.6% (4) 0% 1.2% (1)
Kpaligigbin Neighbouring 44 0% 0% 13.6% (6)
Tasundo No 2 Neighbouring 62 0% 0% 6.5% (4)
Tamabug 6.1% Index 60 1.7% (1) 0% 8.3% (5)
Gushegu Saguli 7.4% Index 56 0% 0% 10.7% (6) 6.9; 0.11
Galiwe Neighbouring 60 3.3% (2) 0% 1.7% (1)
Tinyogu Neighbouring 30 0% 0% 3.3% (1)
Zologu Neighbouring 174 1.1% (2) 0% 3.5% (6)
Wa Kakalapere 6.6% Index 74 5.4% (4) 1.4% (1) 16.2% (12) 7.0; 0.13
Manliyiri Neighbouring 14 0% 0% 28.6% (4)
Dariyiri Neighbouring 43 2.3% (1) 0% 4.7% (2)
Bamkpama Neighbouring 68 1.5% (1) 0% 11.8% (8)
Fooyiri Neighbouring 14 0% 0% 7.1% (1)
Nadowli Moyiri 6.1% Index 83 0% 0% 6.0% (5) 2.0; 0.68
Nayikori Neighbouring 89 3.4% (3) 0% 7.9% (7)
Wiche Neighbouring 15 0% 0% 13.3% (2)
Dancheli Neighbouring 55 0% 0% 7.3% (4)
Mwanwaare Neighbouring 34 0% 0% 2.9% (1)
�As per the methodology used by GHS at the time, the figure represents the highest prevalence reported either in the left or right eye
��Is in proximity to Baale and therefore is both an index and evaluated as a neighbouring community. Where there is more than one index community in a district,
neighbouring communities are only selected for the index community with the highest TF prevalence.
TF: Trachomatous inflammation- follicular; Ct: Chlamydia trachomatis
https://doi.org/10.1371/journal.pntd.0009744.t001
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Fig 2. Map of seroprevalence by cluster, TF trigger investigations and pre-validation surveillance surveys.
https://doi.org/10.1371/journal.pntd.0009744.g002
Table 2. Association between seropositivity and increasing age (1–9 years), TF trigger investigations.
District Index (asterisks) and neighbouring
communities




Baale�, Kema�, Soma, Gbonbondouri, Dani-uuri 2.35; 0.02
West Gonja Mampeasem�, Sakpege, Lukula 2.53; 0.01
Zabzugu-Tatale Mangoase�, Jatoyili, Kpaligigbin, Tasundo No 2 1.36; 0.18
Gushegu Saguli�, Galiwe,Tinyogu, Zologu 1.29; 0.20
Wa Kakalapere�, Manliyiri, Dariyiri, Bamkpama,
Fooyiri
1.56; 0.12




PLOS NEGLECTED TROPICAL DISEASES Peri-elimination trachoma surveillance, Ghana
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009744 September 20, 2021 10 / 16
Discussion
This study explored two approaches to identify recrudescence of trachoma. It provides evi-
dence of heterogeneity in a post-validation setting, with variation in transmission dynamics, as
might have been expected, over a relatively small spatial scale.
Our TF trigger methodology identified one community (Kakalapere) with a 2015–2016 TF
prevalence�5%, anti-Pgp3 seroprevalence >15% and detectable ocular Ct infection and a
neighbouring village with anti-pgp3 antibodies of>25%. When both communities were re-
visited in 2019, there was no evidence of persistent infection or recent Ct transmission. The
evaluation of serological indicators as part of the pre-validation surveillance surveys conducted
in Ghana in 2015–2016, which provided evidence that the country had achieved the elimina-
tion thresholds, reported an overall cluster-summarised mean anti-Pgp3 seroprevalence of
5.5% (95% CI: 4.8–6.3) by ELISA. In and around Baale, in Sawla-Tuna-Kalba, there was evi-
dence of an increase in seropositivity with an increase in age. Considering the community of
Table 3. Clinical, serology and ocular C. trachomatis (Ct) infection data from children aged 1–9 years in index and linked communities visited as part of the infec-
tion and antibody trigger investigations.












Index (Ct infection) 194 4.6% (9) 1.6% (3) 14.4% (28) 14.5; 0.004
Satinjado Linked 62 12.9% (8) 0% 3.2% (2)
Tilpado Linked 127 6.3% (8) 0% 6.3% (8)
Kogni Linked 149 4.7% (7) 0% 4.0% (6)
Sawla-Tuna-
Kalba
Kulwong no. 1 Index (Ct infection) 38 0% 2.6% (1) 5.3% (2) 0.4; 1.0
Kulwong no. 2 Linked 38 7.9% (3) 0% 2.6% (1)
Chechereyili Linked 36 0% 0% 2.8% (1)
Konhinyili Linked 47 0% 0% 4.3% (2)
Kpali Index (no
infection)
79 2.5% (2) 0% 13.9% (11) N/A
Wa Kakalapere Index (Ct infection) 92 0% 0% 3.3% (3) 3.0; 0.84
Manliyiri Index (no
infection) & linked
17 0% 0% 0%
Deryiri Linked 26 0% 0% 0%
Bamkpama Linked 149 1.8% (8) 0% 3.4% (5)
Damwaateng Linked 33 0% 0% 0%
Tuole Index (no
infection)
64 3.1% (2) 0% 6.3% (4) N/A
�Ct infection denotes that the community had Ct infection and an anti-Pgp3 seroprevalence of >15% in 2016.
No infection denotes the community had no Ct infection identified but an anti-Pgp3 seroprevalence of greater than 25% in 2016 (amongst children aged 1–9 years)
https://doi.org/10.1371/journal.pntd.0009744.t003
Table 4. Seroconversion rates (SCR) within communities sampled, infection and antibody trigger investigations.
District Index (and linked) communities SCR 2 (most recent rate, after
point of change)
SCR 1 (historical rate, before
point of change)





Mayido, (Satinjado, Tilpado, Kogni) 2.0 per 100 individuals per year
(95%CI: 1.5–2.6)





Kulwong no1, (Kulwong no2,
Chechereyili, Konhinyili)
0.9 per 100 individuals per year
(95%CI: 0.4–1.5)
5.8 per 100 individuals per year
(95%CI: 3.7–9.1)
11 <0.001
Wa Kakalapere, (Manliyiri, Deryiri,
Bamkpama, Damwaateng)
0.6 per 100 individuals per year
(95%CI: 0.4–0.9)
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Baale itself had a seroprevalence of over 15%, higher than the background seroprevalence rate,
it could be argued that there is some evidence of past low-level transmission. However, this
would be in line with the understanding of transmission dynamics in a post-validation setting
and with no evidence of Ct infection, does not suggest recrudescence [37]. None of the other
communities evaluated in the TF trigger work provided strong evidence of transmission
within the previous nine years and none had current ocular Ct infection. While the TF trigger
methodology was able to provide some evidence of limited Ct infection, it did not reveal signif-
icant onward transmission. A possible explanation for the lack of sustained transmission could
be that there was transient infection in the community that was self-limiting, even if likely
truncated as a result of the three additional rounds of MDA implemented prior to this study.
Even so, the TF trigger approach likely lacks the spatio-temporal power to reliably identify
communities experiencing recrudescence.
Evidence from the antibody and infection trigger data suggested that there has been persis-
tent or repeated re-introduction of Ct infection over a three-year period in Mayido. While the
Ct infection identified by serology could be ocular infection with urogenital Ct strains and
therefore not indicative of trachoma, the convergence of indicators (infection, antibodies and
disease) and household clustering of infections in two consecutive surveys suggests it was tra-
choma. The recent SCR increase seen in Mayido and its linked communities represents further
evidence for on-going acquisition of anti-Ct antibodies and could be a warning sign of recru-
descence. The trigger for programmatic action, whether that might be an absolute value or
change in SCR alone, or one of those things in conjunction with exceeding a seroprevalence or
infection threshold, still needs to be determined. It should be noted that observing an SCR
increase here was only possible because we collected DBS from all ages, allowing for historical
comparisons of transmission rates.
There are potentially other areas of northern Ghana with transmission dynamics similar to
Mayido’s but that were missed as a result of the random sampling methodology that we used.
It is therefore important to better understand the geospatial risk factors associated with on-
going ocular Ct transmission in the post-elimination setting to guide programmes on where to
focus resources for surveillance. We note that communities in and around Mayido differ from
the surrounding population in having residents predominantly from the Konkomba ethnic
group and mostly (66.7%) identifying as traditionalist. 2010 census data for Zabzugu district
(split from Zabzugu-Tatale; containing the communities in question) [38] reported the main
ethnic group of the district as Dagomba, with 36.0% of the population traditionalist. Further
work will be required to understand spatial connectivity and the contextual factors that lead to
re-introduction and facilitation of on-going Ct transmission between individuals [39]. Differ-
ences in social and behavioural practices, especially related to hygiene and sanitation, would
be interesting to explore further.
It has been suggested that the distribution of infection in a peri-elimination setting would
best fit an exponential curve, which has a heavy tail, and that therefore communities with
higher infection prevalence would be occasionally expected. The implicit corollary is that com-
munity prevalence would regress to the mean over time [40]. Regression to the mean has been
observed in hypo-endemic settings in Nepal, Tanzania and the Gambia, where infection disap-
peared in relatively-high-prevalence communities [8,41–44]. The present study demonstrates
that this phenomenon can be either delayed (beyond 10 years) or even fail to occur. We identi-
fied an area in which Ct infection persisted, with transmission potentially increasing post-vali-
dation, many years after district-level MDA was stopped. Interruption of Ct transmission does
not quickly and invariably follow attainment of the criteria for trachoma’s elimination as a
public health problem. If the goal of transmission interruption is to be proposed [45] it should
be noted that it may not occur without additional measures to identify and address such foci.
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Some of the limitations of this study relate to the interpretation of test results. Infection and
antibody tests do not distinguish ocular from urogenital Ct infection, and TF can arise from
other local inflammatory stimuli [46,47]. The reverse catalytic model to calculate SCR may be
an over-simplification of real-world transmission dynamics and estimates could be improved
by using a model based on antibody levels and multiple time points [48]. There are also diffi-
culties in evaluating community prevalence indicators in small communities, such as Man-
liyiri, which reported a large swing in seroprevalence from 28.6% in 2015 to 0% in 2019.
Although every effort was made to reach all children aged 1–9 years, the omission of only a
few children that may have been seropositive or the graduation (in age) of seropositive chil-
dren over the time period, shifting them outside the sampling frame in 2019, would have a
large impact on overall prevalence estimates.
Evidence of transmission between nearby communities could have important implications
for wider recrudescence that may be of concern to programmes. The situation in and around
Mayido is difficult to interpret, as although TF was identified across all four communities,
there was varying anti-Pgp3 seroprevalence, ranging from 3.2% to 14.4% and generally low lev-
els of Ct infection. There may have been low-prevalence Ct infection but it was not identified
either because of the sensitivity of the test, the pooling process used for sample analysis or
issues with swab collection or transport. It would be worthwhile to revisit this area after a min-
imum of two years, to evaluate if there is any evidence of an increase in ocular Ct transmission
mandating programmatic intervention.
Conclusion
There is evidence of heterogeneity in ocular Ct transmission dynamics after validation of tra-
choma elimination as a public health problem, even 10 years after wide-scale MDA has
stopped. There is no suggestion from this study of a threat to elimination thresholds in Ghana.
Elimination thresholds for trachoma are evaluated at the level of the district or administrative
unit with a population of 100,000–250,000. This study has identified on-going transmission at
a smaller geographic scale and the importance of and programmatic implications of such foci
are still to be determined. However, such foci should be routinely observed to monitor poten-
tial recrudescence over a larger geographic scale. There is added value in monitoring anti-Ct
antibodies and Ct infection, either within routine surveillance or to interrogate past strategies.
This can result in a deeper understanding of transmission dynamics and inform new post-vali-
dation surveillance strategies. Opportunities should be explored for integrating infection and
serology-based markers into other infectious disease surveillance surveys conducted in tra-
choma elimination settings.
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